[go: up one dir, main page]

MX2018011666A - Combinaciones farmaceuticas para el tratamiento de cancer. - Google Patents

Combinaciones farmaceuticas para el tratamiento de cancer.

Info

Publication number
MX2018011666A
MX2018011666A MX2018011666A MX2018011666A MX2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A MX 2018011666 A MX2018011666 A MX 2018011666A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
pharmaceutical combinations
inhibitor
combination therapies
Prior art date
Application number
MX2018011666A
Other languages
English (en)
Inventor
Klinghoffer Richard
DEY Joyoti
Original Assignee
Presage Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presage Biosciences Inc filed Critical Presage Biosciences Inc
Publication of MX2018011666A publication Critical patent/MX2018011666A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con terapias de combinación para el tratamiento de cánceres, tales como leucemia, linfoma y cáncer de mama triple negativo. La descripción proporciona terapias de combinación de inhibidores de CDK, por ejemplo, un inhibidor de CDK representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, junto con un inhibidor de BCL-2 o inhibidor de proteasoma para el tratamiento de cáncer.
MX2018011666A 2016-03-28 2017-03-28 Combinaciones farmaceuticas para el tratamiento de cancer. MX2018011666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314356P 2016-03-28 2016-03-28
PCT/US2017/024618 WO2017172826A1 (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018011666A true MX2018011666A (es) 2019-07-08

Family

ID=59966407

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018011666A MX2018011666A (es) 2016-03-28 2017-03-28 Combinaciones farmaceuticas para el tratamiento de cancer.
MX2022002318A MX2022002318A (es) 2016-03-28 2018-09-25 Combinaciones farmaceuticas para el tratamiento de cancer.
MX2022011750A MX2022011750A (es) 2016-03-28 2018-09-25 Combinaciones farmaceuticas para el tratamiento de cancer.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022002318A MX2022002318A (es) 2016-03-28 2018-09-25 Combinaciones farmaceuticas para el tratamiento de cancer.
MX2022011750A MX2022011750A (es) 2016-03-28 2018-09-25 Combinaciones farmaceuticas para el tratamiento de cancer.

Country Status (13)

Country Link
US (5) US11135198B2 (es)
EP (1) EP3436002B1 (es)
JP (3) JP7114478B2 (es)
KR (5) KR102599512B1 (es)
CN (1) CN109689047B (es)
AU (4) AU2017241914B2 (es)
CA (2) CA3018932C (es)
IL (3) IL312398A (es)
MX (3) MX2018011666A (es)
NZ (2) NZ757763A (es)
RU (1) RU2726367C2 (es)
WO (1) WO2017172826A1 (es)
ZA (2) ZA201806819B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10465247B2 (en) 2011-07-01 2019-11-05 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2017172826A1 (en) * 2016-03-28 2017-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
EP3703755B1 (en) * 2017-10-31 2024-07-31 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
CN108261414B (zh) * 2018-01-11 2019-09-06 广西师范大学 一种治疗肺癌的药物组合物
MX2021001764A (es) * 2018-08-14 2021-04-19 Mei Pharma Inc Terapia de combinacion.
US20210353619A1 (en) * 2018-11-01 2021-11-18 Oregon Health & Science University Treatment for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia
MX2021012248A (es) 2019-04-11 2022-03-11 Mei Pharma Inc Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
CN114746095B (zh) * 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
IL297960A (en) * 2020-05-07 2023-01-01 Recurium Ip Holdings Llc conjunctions
IL302925A (en) * 2020-11-19 2023-07-01 Mei Pharma Inc Treatment of kras mutant cancers
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
JP2024516097A (ja) * 2021-04-10 2024-04-12 メイ ファーマ，インク． ボルシクリブ（ｖｏｒｕｃｉｃｌｉｂ）投与レジメンおよびこれを含む治療方法
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7851637B2 (en) 2004-06-17 2010-12-14 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
DK1888550T3 (da) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
WO2006127364A1 (en) 2005-05-24 2006-11-30 Abbott Laboratories Apoptosis promoters
WO2007129062A1 (en) 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2007148158A1 (en) 2006-06-21 2007-12-27 Piramal Life Sciences Limited Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
DK2154971T3 (da) * 2007-05-15 2012-04-02 Piramal Life Sciences Ltd Synergistisk farmaceutisk kombination til behandling af cancer
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CN104220066A (zh) 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
JP6501264B2 (ja) * 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US9241941B2 (en) * 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
CN105246882A (zh) 2013-01-16 2016-01-13 密执安大学评议会 BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法
SG11201507106PA (en) * 2013-03-14 2015-10-29 Onyx Therapeutics Inc Dipeptide and tripeptide epoxy ketone protease inhibitors
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2015084892A1 (en) 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
US9925192B2 (en) 2014-02-28 2018-03-27 Merck Sharp & Dohme Corp. Method for treating cancer
ES2873959T3 (es) * 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
TW201618772A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
US9637488B2 (en) * 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
WO2017172826A1 (en) * 2016-03-28 2017-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer

Also Published As

Publication number Publication date
KR102494039B1 (ko) 2023-01-30
JP2019514854A (ja) 2019-06-06
AU2024200194A1 (en) 2024-02-01
IL261824B (en) 2022-10-01
EP3436002A1 (en) 2019-02-06
KR20230093360A (ko) 2023-06-27
IL295472B2 (en) 2024-10-01
EP3436002A4 (en) 2019-12-04
KR102599512B1 (ko) 2023-11-07
AU2017241914A1 (en) 2018-11-08
IL312398A (en) 2024-06-01
MX2022002318A (es) 2022-04-06
US20200383948A1 (en) 2020-12-10
CA3018932C (en) 2021-10-26
RU2726367C2 (ru) 2020-07-13
MX2022011750A (es) 2022-10-18
ZA201806819B (en) 2022-03-30
KR20190039878A (ko) 2019-04-16
RU2020121147A (ru) 2021-11-03
IL295472B1 (en) 2024-06-01
JP7416872B2 (ja) 2024-01-17
KR20210088016A (ko) 2021-07-13
KR20230156443A (ko) 2023-11-14
AU2020201247A1 (en) 2020-03-12
US20210283104A1 (en) 2021-09-16
CN109689047B (zh) 2025-03-21
AU2017241914B2 (en) 2020-02-27
ZA202107579B (en) 2025-03-26
CN109689047A (zh) 2019-04-26
US11135198B2 (en) 2021-10-05
US20190275004A1 (en) 2019-09-12
JP7114478B2 (ja) 2022-08-08
RU2018137687A (ru) 2020-04-29
US20250221961A1 (en) 2025-07-10
CA3103604A1 (en) 2017-10-05
KR102545392B1 (ko) 2023-06-20
KR102275758B1 (ko) 2021-07-12
KR20230021155A (ko) 2023-02-13
JP2022141916A (ja) 2022-09-29
IL261824A (en) 2018-10-31
RU2018137687A3 (es) 2020-04-29
EP3436002B1 (en) 2025-11-05
IL295472A (en) 2022-10-01
AU2020201247B2 (en) 2021-08-26
AU2021273532A1 (en) 2021-12-16
IL261824B2 (en) 2023-02-01
NZ757763A (en) 2025-07-25
CA3103604C (en) 2023-09-26
AU2021273532B2 (en) 2024-02-01
US20220023261A1 (en) 2022-01-27
NZ747404A (en) 2020-03-27
US12171744B2 (en) 2024-12-24
CA3018932A1 (en) 2017-10-05
US12121508B2 (en) 2024-10-22
JP2024038227A (ja) 2024-03-19
WO2017172826A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
ZA202107579B (en) Pharmaceutical combinations for the treatment of cancer
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
TN2019000210A1 (en) Antitumoral compounds
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CA2983481A1 (en) Janus kinase inhibitor
PH12016502354A1 (en) Pharmaceutical composition
NZ779654A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
MY176235A (en) Compounds that inhibit mcl-1 protein
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2016133903A3 (en) Combination therapy for cancer treatment
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12017501879A1 (en) Methods for treating cancer
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2019003603A (es) Terapia de combinacion con un inhibidor de mek, un inhibidor del eje pd-1 y un taxano.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
TW201613570A (en) Methods for cancer therapy